Press & Publications

Published Stephanie Karzon Published Stephanie Karzon

You'll Probably Be Back: What MDD and TRD Patients Should Really Expect from Psychedelic Therapy and How Care Providers Should Be Talking About It

There's a particular kind of hope that arrives with a first ketamine infusion, or a first psilocybin session. For many people living with Major Depressive Disorder (MDD) or Treatment-Resistant Depression (TRD), it's the first time in years, sometimes ever, that the weight has lifted.

But there's a conversation that doesn't always follow that moment — one that clinicians might not be having, that medical staff don't always know how to approach, and that marketing materials rarely want to touch. It's the conversation about what happens next. When asked directly, clinical staff will be transparent, for the most part. They’ll explain that the therapeutic journey is lifelong, and that psychedelic-assisted therapy is not a magic bullet, nor a promised cure.

Read More
Published Stephanie Karzon Published Stephanie Karzon

Psychedelics for Help with Addiction and Substance Use Disorder

Psychedelics may serve as a potential treatment for addiction, offering a novel approach that targets the emotional, psychological, and neurochemical roots of substance use disorders. Substances like psilocybin and LSD, for example, are believed to disrupt habitual thought patterns and promote introspection, facilitating emotional healing. While ibogaine, the psychoactive alkaloid derived from the iboga plant, can also foster deep insight, it is also believed to help with addiction by modulating the brain’s dopaminergic and opioid systems, reducing withdrawal symptoms and cravings.

Read More
Published Stephanie Karzon Published Stephanie Karzon

Set. Setting. Sound.

This interplay of experimentation, openness, and intention underscores the profound synergy between music and altered states of consciousness, creating not just entertainment, but deeply transformative experiences.

Read More